Page 12 - Bio Developments News Today

Skye Bioscience has announced its plans to develop nimacimab, the company’s monoclonal antibody recently acquired from Bird Rock Bio, for weight loss and the treatment of obesity.

We sat down with Cary Claiborne, CEO and president of Adial Pharma, to discuss the challenges of treating alcohol abuse and company's solution – a serotonin-3 receptor antagonist that could affect neurotransmitters like dopamine and modulate the behavioural effects of alcohol.

CASI Pharmaceuticals and Juventas Cell Therapy recently received approval from China's National Medical Products Administration (NMPA) for Yuanruida, a domestic CD19-targeting CAR-T therapy for relapsed/refractory B-Cell Acute Lymphocytic Leukemia.

Piramal Pharma has launched a high-throughput screening facility at its drug discovery services site in Ahmedabad, India.

London-based sustainable technologies company Johnson Matthey has partnered with biotechnology firm Basecamp Research to adopt more sustainable, bio-based catalysts.

We sat down with Cary Claiborne, CEO and president of Adial Pharma, to discuss the challenges of treating alcohol abuse and company's solution – a serotonin-3 receptor antagonist that could affect neurotransmitters like dopamine and modulate the behavioural effects of alcohol.

Liquid biopsy company Angle has announced the launch of its Portrait+ CTC staining kit at the San Antonio Breast Cancer Symposium (SABCS).

Pfizer is discontinuing danuglipron, its twice-daily weight loss pill, after more than half of patients in a clinical trial stopped taking it.

GSK CEO Emma Walmsley has told Reuters that the company’s respiratory syncytial virus (RSV) vaccine is expected to make over $1.26 billion in its first year on the market.

Lumen Bioscience, a clinical-stage biopharma company developing biologic drugs for highly prevalent disease, has received $5.5 million in new funding from the U.S. Department of Defense, to develop technologies for needle-free vaccines.